Developing a Radionuclide TLR-7 Immunostimulatory Dual Payload ADC to Achieve In Situ Anti-Tumor Vaccination Response
- Describing dual payload ADC conjugation strategy and physicochemical properties to demonstrate co-delivery therapeutic benefit versus single payload therapies
- Exploring biodistribution data and in-human dosimetry calculations to predict safe radiation exposure
- Evaluating immunological and imaging studies to achieve in situ vaccination response